Arixtra - direct healthcare professional communication (DHPC)

fondaparinux sodium

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Arixtra (fondaparinux sodium): Serious quality defect related to the needle in pre-filled syringe

Key facts

• Medicine name:
  Arixtra
• Active substance:
  fondaparinux sodium
• Therapeutic area (MeSH):
  • Venous Thrombosis
  • Pulmonary Embolism
  • Myocardial Infarction
  • Angina, Unstable
• DHPC type:
  Quality defect
• Human ATC codes:
  B01AX05
• Dissemination date:
  06/02/2026